Validation of the 2018 FIGO cervical cancer staging system.

ABSTRACT:

Objective

To validate the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer, with a particular focus on stage IB and stage III disease.

Methods

Two retrospective cohort studies were conducted using The Surveillance, Epidemiology, and End Results Program between 1988 and 2014. The stage IB cohort consisted of node-negative FIGO stage IB1 (tumor size <2 cm), IB2 (2-3.9 cm), and IB3 (≥4 cm) cervical cancer. The stage III cohort consisted of FIGO stage IIIA, IIIB, and stage IIIC1 (any pelvic nodal metastasis) cervical cancer. Multivariable analysis was performed for cause-specific survival based on cancer stage.

Results

In the stage IB cohort (n = 8909), stage IB1 tumors were more likely to be adenocarcinoma and l

SUBMITTER: Matsuo K 

PROVIDER: S-EPMC7528458 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature